ebook: Antibody detection for cancer research
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
List view / Grid view
Gain more insight into immune-tumor interactions and learn how antibody detection techniques like multiplexing is advancing immunotherapies.
In this short video we show an example of a 3D airway organoid model along with some interesting ways to get the most out of this type of assay.
The UK has launched the Pandemic Preparedness Partnership which will advise the G7 Presidency how to reduce vaccine development time from 300 to 100 days.
A candidate vaccine has shown potential against MERS in non-human primates, when administered intradermally.
Accelerate your research with an upgradeable platform. Benefit from a fluidic-free assay format for easy and fast kinetics or analyte quantitation.
Biliverdin attaches to a region of the SARS-CoV-2 Spike protein, stabilising it so that it is not able to expose its structure to antibodies, a new study has shown.
Using newly developed assays, researchers have characterised the antibody response of individuals infected with SARS-CoV-2.
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
A new COVID-19 vaccine could provide protection from severe infection from a range of coronaviruses, studies in pigs have shown.
14 April 2021 | By Fluidigm
Watch our free on-demand webinar to learn more about using Imaging Mass Cytometry™ (IMC™) to measure over 40 protein targets with subcellular resolution.
Discover how a new ELISA against S1-RBD for COVID-19 seroconversion detection can accelerate discovery to facilitate vaccine breakthroughs.
Children with multisystem inflammatory syndrome have a unique immunological profile revealed by systems-level analyses.
A new VLP-based Zika virus vaccine is able to protect mice completely from infection, researchers have found.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
This ebook includes articles discussing why biomaterial and nanoparticle-based formulations could lead to the next generation of vaccines and exploring how a new rhinovirus vaccine showed promise in pre-clinical studies.